The pharmacokinetic advantage of 5-methyltetrahydrofolate for minimization of the risk for birth defects
| Autor: | June E. Ayling, Steven W. Bailey |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine Treatment outcome lcsh:Medicine Physiology 5-Methyltetrahydrofolate Folic Acid Deficiency Article Congenital Abnormalities Plasma Young Adult 03 medical and health sciences Folic Acid Pharmacokinetics Pregnancy medicine Humans Young adult lcsh:Science Tetrahydrofolates 030109 nutrition & dietetics Multidisciplinary business.industry lcsh:R medicine.disease Pregnancy Complications Regimen Treatment Outcome 030104 developmental biology Folic acid Plasma chemistry Female lcsh:Q business |
| Zdroj: | Scientific Reports, Vol 8, Iss 1, Pp 1-7 (2018) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-018-22191-2 |
| Popis: | Despite efforts to increase folic acid (FA) intake, even within countries mandating FA fortification, there remain pregnant women with folate levels inadequate to minimize congenital disorders (e.g., of the neural tube, heart, and lip/palate). The pharmacokinetics of FA and [6S]-5-methyltetrahydrofolate (5-MTHF) were examined to find a reliable and minimal dose for rapidly rescuing folate status prior to critical periods of embryonic development. Serum total folate increased much more rapidly over the first four days in insufficient women given 7.5 mg doses of 5-MTHF than the same regimen of FA (P for trend |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|